Baxter Q2 Earnings Marginally Beat Estimates; Revises Upper End Of 2021 EPS Outlook

  • Baxter International Inc BAX Q2 revenue of $3.1 billion, in line with the consensus, increased 14% on a reported basis, 9% on a constant currency basis, and 8% on an operational basis.
  • Adjusted EPS of $0.80 increased 25% and surpassed the estimate of $0.75.
  • Among Baxter's product categories, growth was led by BioPharma Solutions, Advanced Surgery, and Medication Delivery, which each delivered double-digit growth.
  • Acute Therapies grew at low single digits on a reported basis and declined mid-single digits at constant currency rates, reflecting a challenging comparison due to surging product demand this time last year related to the COVID-19 pandemic.
  • The gross margin expanded from 38.2% to 39.8%, and the operating margin improved from 12.2% to 13.7%.
  • Outlook: Baxter expects full-year 2021 sales growth of approximately 8% on a reported basis, 5% to 6% on a constant currency basis, and 4% to 5% on an operational basis. It expects an adjusted EPS of $3.49 - $3.55, versus the $3.40 consensus.
  • For Q3, the Company sees sales growth of approximately 7% on a constant currency basis, 6% on an operational basis. It expects an adjusted EPS of $0.93 to $0.95.
  • The Company is reportedly in talks to acquire Hill Rom.
  • Price Action: BAX shares closed at $81.91 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!